Cargando…
Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324802/ https://www.ncbi.nlm.nih.gov/pubmed/35877241 http://dx.doi.org/10.3390/curroncol29070381 |
_version_ | 1784756888375656448 |
---|---|
author | Tanaka, Takashi Takata, Kazuhide Yokoyama, Keiji Fukuda, Hiromi Yamauchi, Ryo Fukunaga, Atsushi Shakado, Satoshi Sakisaka, Shotaro Hirai, Fumihito |
author_facet | Tanaka, Takashi Takata, Kazuhide Yokoyama, Keiji Fukuda, Hiromi Yamauchi, Ryo Fukunaga, Atsushi Shakado, Satoshi Sakisaka, Shotaro Hirai, Fumihito |
author_sort | Tanaka, Takashi |
collection | PubMed |
description | Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment for u-HCC in a real-world setting. Methods: This retrospective study was conducted between January 2021 and April 2022. Twenty-eight patients with u-HCC, who were treated with ATZ + BV, were assessed for their treatment response, continuation, and adverse events (AEs). Results: Among the 28 patients, 24 were evaluated at the first imaging. The objective response rate (ORR) was 29.2% (n = 7), and 54.2% (n = 13) on the response evaluation criteria in solid tumors (RECIST 1.1) and in the modified RECIST (mRECIST) guidelines, respectively. Comparing the objective response (OR) group (n = 13) and the non-OR group (n = 11), the modified albumin–bilirubin (mALBI) grades 1 and 2a were found to be significant predictive factors for OR (p = 0.021) in the mRECIST guidelines. Among the 28 patients, 17 discontinued their treatment due to AEs. Comparing the treatment continuation (n = 11) and discontinuation groups (n = 17), a Child–Pugh score of five points (p = 0.009) and mALBI grades 1 and 2a (p = 0.020) were predictive factors with significant differences. Conclusions: Pretreatment mALBI grades 1 and 2a were the important predictive factors associated with the therapeutic response and the therapeutic continuation of ATZ + BV for patients with u-HCC. |
format | Online Article Text |
id | pubmed-9324802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93248022022-07-27 Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma Tanaka, Takashi Takata, Kazuhide Yokoyama, Keiji Fukuda, Hiromi Yamauchi, Ryo Fukunaga, Atsushi Shakado, Satoshi Sakisaka, Shotaro Hirai, Fumihito Curr Oncol Communication Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment for u-HCC in a real-world setting. Methods: This retrospective study was conducted between January 2021 and April 2022. Twenty-eight patients with u-HCC, who were treated with ATZ + BV, were assessed for their treatment response, continuation, and adverse events (AEs). Results: Among the 28 patients, 24 were evaluated at the first imaging. The objective response rate (ORR) was 29.2% (n = 7), and 54.2% (n = 13) on the response evaluation criteria in solid tumors (RECIST 1.1) and in the modified RECIST (mRECIST) guidelines, respectively. Comparing the objective response (OR) group (n = 13) and the non-OR group (n = 11), the modified albumin–bilirubin (mALBI) grades 1 and 2a were found to be significant predictive factors for OR (p = 0.021) in the mRECIST guidelines. Among the 28 patients, 17 discontinued their treatment due to AEs. Comparing the treatment continuation (n = 11) and discontinuation groups (n = 17), a Child–Pugh score of five points (p = 0.009) and mALBI grades 1 and 2a (p = 0.020) were predictive factors with significant differences. Conclusions: Pretreatment mALBI grades 1 and 2a were the important predictive factors associated with the therapeutic response and the therapeutic continuation of ATZ + BV for patients with u-HCC. MDPI 2022-07-08 /pmc/articles/PMC9324802/ /pubmed/35877241 http://dx.doi.org/10.3390/curroncol29070381 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Tanaka, Takashi Takata, Kazuhide Yokoyama, Keiji Fukuda, Hiromi Yamauchi, Ryo Fukunaga, Atsushi Shakado, Satoshi Sakisaka, Shotaro Hirai, Fumihito Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title | Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_full | Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_fullStr | Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_full_unstemmed | Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_short | Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma |
title_sort | pretreatment modified albumin–bilirubin grade is an important predictive factor associated with the therapeutic response and the continuation of atezolizumab plus bevacizumab combination therapy for patients with unresectable hepatocellular carcinoma |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324802/ https://www.ncbi.nlm.nih.gov/pubmed/35877241 http://dx.doi.org/10.3390/curroncol29070381 |
work_keys_str_mv | AT tanakatakashi pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma AT takatakazuhide pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma AT yokoyamakeiji pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma AT fukudahiromi pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma AT yamauchiryo pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma AT fukunagaatsushi pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma AT shakadosatoshi pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma AT sakisakashotaro pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma AT hiraifumihito pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma |